-
公开(公告)号：US20150259401A1
公开(公告)日：2015-09-17
申请号：US14656149
申请日：2015-03-12
Applicant: Janssen Biotech, Inc.
Inventor： Thomas Nesspor , Bernard Scallon
CPC classification number: C07K16/1027 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/524 , C07K2317/72 , C07K2317/94
Abstract: The antibodies, immunoglobulin constructs, or immunoglobulin fusion proteins whose in vivo half-life is increased in ferrets by a modified ferret IgG Fc region can be useful to test therapeutics in ferrets and ferret models.
Abstract translation: 抗体，免疫球蛋白构建体或免疫球蛋白融合蛋白，其体内半衰期通过修饰的白鼬IgG Fc区在雪貂中增加可用于测试雪貂和白鼬模型中的治疗。
-
公开(公告)号：US20140057319A1
公开(公告)日：2014-02-27
申请号：US13974655
申请日：2013-08-23
Applicant: Janssen Biotech, Inc.
Inventor： Michael Naso , T.Shantha Raju , Bernard Scallon
IPC: C07K16/24
CPC classification number: C12N9/2402 , C07K16/00 , C07K16/241 , C07K2317/41 , C07K2317/72 , C07K2317/732 , C12N15/85 , C12P21/005 , C12Y302/01018
Abstract: The properties of an Fc-containing protein, for example, an antibody, are controlled by altering the sialylation of the oligosaccharides in the Fc region by transfecting the cell line expressing the Fc-containing protein with a vector sequence encoding a sialidase. The modified Fc-containing proteins have therapeutic utility in diseases or conditions in which it is desirable to control the affinity for one or more of the FcγRI, FcγRIIA, and FcγRIIIA receptors, ADCC activity, macrophage or monocyte activation, serum half-life, and avidity.
Abstract translation: 通过用编码唾液酸酶的载体序列转染表达含Fc的蛋白质的细胞系，通过改变Fc区中寡糖的唾液酸化来控制含Fc的蛋白质，例如抗体的性质。 经修饰的含Fc蛋白质具有治疗效用，其中希望控制对FcγRα，FcγRIIA和FcγRIIIA受体的一种或多种的亲和力，ADCC活性，巨噬细胞或单核细胞活化，血清半衰期和 亲和力
-
公开(公告)号：US20190085069A1
公开(公告)日：2019-03-21
申请号：US16209326
申请日：2018-12-04
Applicant: Janssen Biotech, Inc.
Inventor： Jill Giles-Komar , George Heavner , David Knight , Jinquan Luo , David Peritt , Bernard Scallon , David Shealy
IPC: C07K16/24 , C07K14/54 , A61K45/06 , A61K39/395 , A61K38/27 , A61K31/56 , A61K31/137 , A61K51/00 , C12Q1/6876 , A61K39/00
Abstract: An anti-IL-12 antibody or fragment thereof that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody or fragment thereof, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
-
公开(公告)号：US20180334500A1
公开(公告)日：2018-11-22
申请号：US15583487
申请日：2017-05-01
Applicant: Janssen Biotech, Inc.
Inventor： Jill Giles-Komar , David M. Knight , David Peritt , Bernard Scallon , David Shealy
IPC: C07K16/24 , A61K45/06 , A61K39/395 , A61K39/00
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
-
公开(公告)号：US09708410B2
公开(公告)日：2017-07-18
申请号：US13623144
申请日：2012-09-20
Applicant: Janssen Biotech, Inc.
Inventor： G. Mark Anderson , Bernard Scallon , Michael Naso , Ann Cai , Cam Holland
IPC: A61K39/395 , C07K16/36 , C07K16/30 , A61K39/00
CPC classification number: C07K16/36 , A61K9/0019 , A61K31/4164 , A61K39/3955 , A61K47/6849 , A61K51/00 , A61K2039/505 , A61K2039/507 , C07K16/30 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3069 , C07K2317/24 , C07K2317/52 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.
-
Patent Agency Ranking
26.发明授权公开(公告)号：US09409984B2
公开(公告)日：2016-08-09
申请号：US14190893
申请日：2014-02-26
Applicant: Janssen Biotech, Inc.
Inventor： Jill Giles-Komar , David M. Knight , David Peritt , Bernard Scallon , David Shealy
IPC: A61K39/395 , C07K16/24 , A61K45/06 , A61K39/00
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
Abstract translation: 分离的抗IL-12抗体，编码抗体或抗体部分的核酸，载体，宿主细胞和制备方法可用于产生用于治疗和/或诊断IL-12相关病症，疾病和障碍的抗体或部分， 如牛皮癣。
-
公开(公告)号：US20150147805A1
公开(公告)日：2015-05-28
申请号：US14617003
申请日：2015-02-09
Applicant: Janssen Biotech, Inc.
Inventor： Jill Carton , Jin Lu , Bernard Scallon , Linda Snyder
CPC classification number: C07K16/00 , C07K2317/14 , C07K2317/56 , C07K2319/036 , C12N15/85 , C12N2800/22
Abstract: Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids.
Abstract translation: 抗体表达载体和质粒可以掺入用于转录抗体DNA的各种抗体基因部分和抗体在合适的宿主细胞中的表达。 表达载体和质粒具有有利于将抗体编码DNA连接到载体中的限制酶位点。 载体包含增强子和启动子序列，其可以变化以与宿主细胞中的转录因子相互作用，从而控制抗体编码DNA的转录。 试剂盒可以并入这些载体和质粒。
-
公开(公告)号：US08975040B2
公开(公告)日：2015-03-10
申请号：US13974655
申请日：2013-08-23
Applicant: Janssen Biotech, Inc.
Inventor： Michael Naso , T. Shantha Raju , Bernard Scallon
CPC classification number: C12N9/2402 , C07K16/00 , C07K16/241 , C07K2317/41 , C07K2317/72 , C07K2317/732 , C12N15/85 , C12P21/005 , C12Y302/01018
Abstract: The properties of an Fc-containing protein, for example, an antibody, are controlled by altering the sialylation of the oligosaccharides in the Fc region by transfecting the cell line expressing the Fc-containing protein with a vector sequence encoding a sialidase. The modified Fc-containing proteins have therapeutic utility in diseases or conditions in which it is desirable to control the affinity for one or more of the FcγRI, FcγRIIA, and FcγRIIIA receptors, ADCC activity, macrophage or monocyte activation, serum half-life, and avidity.
Abstract translation: 通过用编码唾液酸酶的载体序列转染表达含Fc的蛋白质的细胞系，通过改变Fc区中寡糖的唾液酸化来控制含Fc的蛋白质，例如抗体的性质。 经修饰的含Fc蛋白质具有治疗效用，其中希望控制对FcγRI，FcγRIIA和FcγRIIIA受体的一种或多种的亲和力，ADCC活性，巨噬细胞或单核细胞活化，血清半衰期和 亲和力
-
公开(公告)号：US11078267B2
公开(公告)日：2021-08-03
申请号：US16677120
申请日：2019-11-07
Applicant: Janssen Biotech, Inc.
Inventor： Jill Giles-Komar , David M. Knight , David Peritt , Bernard Scallon , David Shealy
IPC: A61K39/395 , C07K16/24 , A61K45/06 , A61K39/00
Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
-
公开(公告)号：US20190248884A1
公开(公告)日：2019-08-15
申请号：US16284316
申请日：2019-02-25
Applicant: Janssen Biotech, Inc.
Inventor： Jill Giles-Komar , David M. Knight , David Peritt , Bernard Scallon , David Shealy
IPC: C07K16/24 , A61K39/395 , A61K45/06
Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
-
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.031 seconds)
